We had broken the store about Jubilant Organosys deal with Syngenta earlier this week. Citi in a report releases just a while ago continues to be bullish on Jubilant after the Syngenta deal.
Jubilant’s CRAMS business has got a shot in the arm in the form of a “multi-million” dollar 5-year contract with Syngenta to supply pyridines. Jubilant’s CRAMS business has grown at 45% CAGR (excluding acquisitions) over FY05-07, and this contract further improves the likelihood that this growth trend would sustain.
Jubilant is a leading player in pyridines & recently raised its capacity by c24% to 42000 TPA. These are key intermediates used in multiple pharma & agrochem APIs. Jubilant has over 150 derivatives in its product basket that are used in c229 APIs & 17 agrochem products. With the expanded capacity, Jubilant becomes the global leader in pyridines.
Jubilant as one of the superior Indian outsourcing plays, given its integrated presence across the pharma & chemicals value chain. The company is expected to report an EPs of Rs 17.57 and Rs 22.52 for FY08 and FY09 respectively. Citi reiterates a BUY with a price target of Rs 387.